ERBB2 and breast carcinoma: Although this subtype of breast cancer has been historically associated with poor outcomes, the development of anti-HER2-targeted therapies has notably increased the median progression-free survival (PFS) and overall survival (OS) of patients (Slamon et al., 2001; Dawood et al., 2010; Swain et al., 2013; Mendes et al., 2015; Swain et al., 2015; Jain et al., 2018; Tripathy et al., 2020).